• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Double Stem Cell Transplant Feasible for Some With Multiple Myeloma

by | Jun 19, 2024 | Uncategorized

Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More

Double Stem Cell Transplant Feasible for Some With Multiple Myeloma

by | Jun 19, 2024 | Uncategorized

Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More

Double Stem Cell Transplant Feasible for Some With Multiple Myeloma

by | Jun 19, 2024 | Uncategorized

Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More

Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy

by | Jun 19, 2024 | Uncategorized

EJHaem. 2024 Apr 30;5(3):485-493. doi: 10.1002/jha2.907. eCollection 2024 Jun. ABSTRACT Belantamab mafodotin is the first-in-class antibody-drug conjugates targeting B-cell maturation antigen to have demonstrated effectiveness in triple-class refractory multiple...

VIDEO: Oral drug regimen well tolerated in older patients with multiple myeloma

by | Jun 18, 2024 | Uncategorized

CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about a study in older patients with relapsed/refractory multiple myeloma.The study was presented at ASCO Annual Meeting and investigated an oral two-drug regimen for frail patients with...

VIDEO: Belantamab mafodotin ‘comeback kid’ for relapsed refractory multiple myeloma

by | Jun 17, 2024 | Uncategorized

CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.A previous study assessing belantamab mafodotin monotherapy for the treatment of relapsed refractory multiple myeloma did...
« Older Entries
Next Entries »

Recent Content

  • Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome
  • Myeloma Awareness Month and Acknowledging Early Symptoms of The Disease
  • Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
  • Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
  • Correction: Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Genetic Study Sheds Light on Inherited Risk of Multiple Myeloma
  • A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
  • Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma
  • Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
  • Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT